<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797091</url>
  </required_header>
  <id_info>
    <org_study_id>Kidney in COVID-19</org_study_id>
    <nct_id>NCT04797091</nct_id>
  </id_info>
  <brief_title>Kidney in Coronavirus Disease 2019 Registry</brief_title>
  <acronym>KidneyCOVID19</acronym>
  <official_title>Kidney in Coronavirus Disease 2019 Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SARS-CoV-2 virus is a virus newly identified in January 2020. The WHO defined COVID-19 as&#xD;
      a health emergency of international importance. The clinical manifestation of the COVID-19&#xD;
      disease cannot be fully described in the short time.&#xD;
&#xD;
      First insights in patients suffering from acute kidney injury (AKI) during COVID-19 indicate&#xD;
      severe course with high mortality. The locally varying spread of SARS CoV-2 infection&#xD;
      requires a better understanding of clinical course of COVID-19 in order to be able to&#xD;
      establish future treatment approaches.&#xD;
&#xD;
      The examination of attributable mortality and costs of COVID-19 will need to be studied on a&#xD;
      multinational basis and therefore Kidney in COVID-19 Registry will particularly use a matched&#xD;
      case control design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SARS-CoV-2 virus is a virus newly identified in January 2020 in Wuhan, China, which&#xD;
      belongs to the group of coronaviruses and causes COVID-19. Due to the rapid spread worldwide,&#xD;
      high morbidity and virulence the of causing SARS-CoV-2 , the WHO defined COVID-19 as a health&#xD;
      emergency of international importance in February 2020. Due to the rapid spread of the new&#xD;
      virus, a comprehensive understanding of the transmission, the course of the disease, the&#xD;
      diagnosis and the therapeutic regimen is of the utmost importance. Initial case reports&#xD;
      indicate that human-to-human transmission takes place through droplet infection. In contrast&#xD;
      to previously known infections from the group of coronaviruses, the SARS-CoV-2 virus has a&#xD;
      high ability to infect with already mild symptoms resulting in frequent outbreak situation of&#xD;
      worldwide importance. Furthermore, high viral loads are found in the upper respiratory tract&#xD;
      of infected people leading to the high virulence of causing SARS-CoV-2. The clinical&#xD;
      manifestation of the COVID-19 disease cannot be fully described in the short time. However,&#xD;
      symptoms of SARS-CoV-2 virus infection are described with mild symptoms like fever, muscle&#xD;
      pain, and dry cough as well as severe complications like virus pneumonia, Acute Respiratory&#xD;
      Distress Syndrome (ARDS) and death. Interestingly older and chronically ill patients in&#xD;
      particular have a severe course of COVID-19 with intensive care treatment and high mortality.&#xD;
      At present, there is no specific therapy available for COVID-19. Treatment approaches are&#xD;
      primarily supportive with admission of patients to the intensive care unit (ICU), mechanical&#xD;
      ventilation, extracorporeal membrane oxygenation (ECMO) and maintenance of fluid and&#xD;
      electrolyte balance. Patients with severe renal insufficiency and fluid retention, pulmonary&#xD;
      edema or hyperkalemia may require dialysis. First insights in patients suffering from acute&#xD;
      kidney injury (AKI) during COVID-19 indicate severe course with high mortality. First case&#xD;
      reports do not describe a beneficial effect of antiviral therapy. The locally varying spread&#xD;
      of SARS CoV-2 infection requires a better understanding of clinical course of COVID-19 in&#xD;
      order to be able to establish future treatment approaches. Investigators have to attach great&#xD;
      importance to high-risk cohorts like patients suffering from chronic renal disease with many&#xD;
      comorbidities or patients after kidney transplantation under immunosuppressive drug&#xD;
      treatment. Although COVID-19 has been studied for only a few month it is known that&#xD;
      especially these patients develop a severe clinical course. Due to increasingly frequent&#xD;
      outbreak situations and globally chances in species distributions, local, as well as&#xD;
      worldwide surveillances in epidemiology and species distribution are urgently needed. As the&#xD;
      clinical course of COVID-19 disease is dependent on the causing viral pathogen and the full&#xD;
      picture of clinical manifestation is not yet understand further studies with regard to the&#xD;
      disease course are mandatory.&#xD;
&#xD;
      Additionally, the examination of attributable mortality and costs of COVID-19 will need to be&#xD;
      studied on a multinational basis and therefore Kidney in COVID-19 Registry will particularly&#xD;
      use a matched case control design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the global incidence of SARS-CoV-2 infections</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the global incidence of SARS-CoV-2 infections and the resulting effects on kidney function as well as monitoring of global and local developments over time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the incidence of acute kidney damage in the context of SARS-CoV2 infections</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the incidence of acute kidney damage in the context of SARS-CoV2 infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of risk groups and risk factors</measure>
    <time_frame>6 months</time_frame>
    <description>Identification of risk groups and risk factors by examining SARS-CoV-2 infections in patients with chronic kidney disease and kidney transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of mortality rates due to SARS-CoV-2 infections</measure>
    <time_frame>6 months</time_frame>
    <description>Documentation of mortality rates in % in comparison to case controls enrolled in the same hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of additional costs due to SARS-CoV-2 infections</measure>
    <time_frame>6 months</time_frame>
    <description>Documentation of additional costs in euros in comparison to case controls enrolled in the same hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess increasing costs associated with SARS-CoV-2-infections</measure>
    <time_frame>6 months</time_frame>
    <description>To assess increasing costs associated with SARS-CoV-2-infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze the effect of SARS-CoV-2-infections on the kidney by means of eGFR</measure>
    <time_frame>6 months</time_frame>
    <description>To analyze the effect of SARS-CoV-2 infections on kidney function as determined by estimated Glomerular Filtration Rate (eGFR) after SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze the effect of SARS-CoV-2-infections on the kidney by means of maximum creatinine</measure>
    <time_frame>6 months</time_frame>
    <description>To analyze the effect of SARS-CoV-2 infections on kidney function as determined by maximum creatinine after SARS-CoV-2 infection</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Patients with SARS-CoV-2-infection</arm_group_label>
    <description>Patients with evidence of SARS-CoV-2-infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Controls will be identified retrospectively at the same hospitals that based on matching of demographics, underlying diseases and duration of hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Retrospective data collection</intervention_name>
    <description>Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Patients with SARS-CoV-2-infection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Particularly, controls will be identified retrospectively at the same hospitals that based&#xD;
        on matching of demographics, underlying diseases and duration of hospitalization (i.e. one&#xD;
        control per case, both in the same hospital).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Virology evidence of SARS-CoV-2-infection&#xD;
&#xD;
          -  Pathological evidence of SARS-CoV-2-infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Occurrence of ARDS (acute respiratory distress syndrome) without evidence of&#xD;
             SARS-CoV-2 infection&#xD;
&#xD;
          -  Acute kidney injury without evidence of SARS-CoV-2 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Burst, PD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felix KÃ¶hler, MD</last_name>
    <phone>+4922147897222</phone>
    <email>felix.koehler@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victor Suarez, MD</last_name>
    <phone>+4922147897222</phone>
    <email>victor.suarez@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Burst, MD</last_name>
      <phone>+49(0)221 478 86285</phone>
      <email>volker.burst@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Victor Suarez, MD</last_name>
      <email>victor.suarez@uk-koeln.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Volker Burst</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

